Earnings Warning Season is Here: Strategies to Benefit from Others' Struggles.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2025
0mins
Should l Buy REGN?
Source: Barron's
- Investor Sentiment: January is typically a time of optimism for investors, reflecting a hopeful outlook for the year ahead.
- Corporate Challenges: Despite investor optimism, corporate America may face significant challenges that could impact performance and growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 746.580
Low
637.00
Averages
808.50
High
1057
Current: 746.580
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sanofi Q1 Results Exceed Market Expectations
- Strong Performance: Sanofi reported total sales of €10.51 billion ($12.29 billion) for Q1, surpassing analyst expectations of €10.22 billion, indicating robust market performance that is likely to boost investor confidence.
- Profit Growth: Quarterly business operating income reached €2.97 billion ($3.47 billion), exceeding the average analyst estimate of €2.85 billion, reflecting significant progress in cost control and operational efficiency.
- Dupixent Sales Surge: Sales of Dupixent rose by 30.8% to €4.17 billion ($4.88 billion), far exceeding analysts' expectations of €3.89 billion, demonstrating sustained demand for the drug in asthma and eczema treatment, thereby reinforcing Sanofi's market position.
- Executive Transition Impact: Following the ousting of former CEO Paul Hudson due to failure to revitalize the drug pipeline, new CEO Belén Garijo is set to take over at the end of April, which may lead to strategic shifts affecting future R&D and market strategies.
See More
Regeneron Launches Gene Therapy and Lowers Drug Prices
- Free Gene Therapy: Regeneron announced that its recently FDA-approved gene therapy, Otarmeni, will be provided free of charge in the U.S. to address an ultra-rare form of genetic hearing loss, enhancing the company's image as a socially responsible biopharma leader.
- Drug Price Adjustments: The company will lower Medicaid prices to match those in other developed nations, notably reducing the price of its blockbuster drug Praluent from approximately $537 to $225, which is expected to significantly alleviate patient financial burdens and enhance market competitiveness.
- R&D Investment Commitment: Regeneron has committed over $9 billion to bolster domestic R&D and manufacturing capabilities over the coming years, a strategic investment that will strengthen its innovation and production capacity in the global biopharma market.
- Policy Context and Market Reaction: As the final biopharma firm to sign Trump's drug pricing agreement, Regeneron's actions align with policy expectations and may improve its investor perception, with bullish sentiment reflected on Stocktwits, despite the stock's 0.8% decline year-to-date.
See More
Trump's Fake Math Claims Spark Controversy
- False Drug Pricing Claims: During a deal announcement with Regeneron, Trump claimed drug prices had been cut by over 100%, a mathematically impossible assertion that reflects a misunderstanding of drug pricing, potentially undermining public trust in his policies.
- Exaggerated Discount Claims: Trump admitted to previously stating that drug prices were reduced by '500% to 600%', attempting to justify this with 'different calculations', yet such claims lack mathematical validity, risking consumer misconceptions about drug pricing.
- Misjudged Iran War Timeline: At the same event, Trump inaccurately claimed the Iran war would conclude within his predicted four to six weeks, while it has actually lasted over seven weeks, which could affect public perception of his foreign policy effectiveness.
- Crowd Size Controversy Resurfaces: Trump revisited the crowd size debate from his 2017 inauguration while discussing renovations at the Lincoln Memorial, claiming it matched Martin Luther King Jr.'s rally, despite lacking supporting evidence, which may further erode his credibility.
See More
Regeneron Lowers Drug Prices and Offers Gene Therapy for Free
- Price Reduction Agreement: Regeneron has agreed to lower drug prices for some Americans as part of a deal with the Trump administration, which may enhance the company's competitive position in the market amid increasing regulatory scrutiny on drug pricing.
- Free Gene Therapy Offering: Following FDA approval, Regeneron will provide its first hearing-loss gene therapy, Otarmeni, for free to eligible U.S. patients, demonstrating the company's commitment to patient care while potentially attracting more users to its innovative products.
- Policy Context: This agreement is part of Trump's 'most favored nation' initiative aimed at tying U.S. drug prices to the lowest prices in other developed countries, and Regeneron's involvement may encourage other pharmaceutical companies to adopt similar pricing strategies.
- Market Potential Assessment: Piper Sandler analysts estimate that the gene therapy could achieve peak sales of $130 million, reflecting the market potential of this treatment for an ultra-rare genetic condition, which could significantly contribute to Regeneron's revenue growth.
See More
Regeneron Agrees to Lower Drug Prices Under Trump Deal
- Price Reduction Agreement: Regeneron has agreed to lower drug prices for some Americans as part of a deal with President Trump, addressing growing concerns over drug affordability and potentially enhancing the company's public image.
- Free Gene Therapy Offering: Following FDA approval, Regeneron will provide its first hearing-loss gene therapy, Otarmeni, for free to eligible U.S. patients, showcasing the company's commitment to social responsibility while attracting more patients to its innovative products.
- Competitive Market Advantage: This agreement is part of Trump's 'most favored nation' policy, which aims to tie U.S. drug prices to the lowest prices in other developed countries, granting Regeneron greater pricing flexibility in a competitive biopharmaceutical market.
- Sales Potential Forecast: Analysts estimate that Otarmeni gene therapy could achieve peak sales of $130 million, reflecting strong market demand and potentially generating significant revenue growth for Regeneron, thereby solidifying its position in the biopharmaceutical sector.
See More
Regeneron's Gene Therapy Otarmeni Receives FDA Accelerated Approval
- FDA Accelerated Approval: Regeneron's gene therapy Otarmeni has received accelerated approval from the FDA, aimed at treating hearing loss caused by gene mutations, marking a significant advancement for the company in the otology treatment space.
- Eligible Patient Population: The therapy is available for adults and children with biallelic variants in the OTOF gene, particularly those with severe-to-profound sensorineural hearing loss who have not undergone cochlear implantation in the same ear, potentially offering new treatment options for this demographic.
- Clinical Trial Support: Data from the company's CHORD trial indicates that 16 out of 20 subjects exceeded a predetermined hearing level 24 weeks after receiving Otarmeni, demonstrating the therapy's efficacy and laying the groundwork for future market introduction.
- Conditions for Continued Approval: The ongoing approval of the drug will depend on positive results from the confirmatory trial, which is currently enrolling patients in countries including the U.S. and the U.K., reflecting Regeneron's commitment to further validating the therapy's effectiveness.
See More
Sanofi Q1 Results Exceed Market Expectations
- Strong Performance: Sanofi reported total sales of €10.51 billion ($12.29 billion) for Q1, surpassing analyst expectations of €10.22 billion, indicating robust market performance that is likely to boost investor confidence.
- Profit Growth: Quarterly business operating income reached €2.97 billion ($3.47 billion), exceeding the average analyst estimate of €2.85 billion, reflecting significant progress in cost control and operational efficiency.
- Dupixent Sales Surge: Sales of Dupixent rose by 30.8% to €4.17 billion ($4.88 billion), far exceeding analysts' expectations of €3.89 billion, demonstrating sustained demand for the drug in asthma and eczema treatment, thereby reinforcing Sanofi's market position.
- Executive Transition Impact: Following the ousting of former CEO Paul Hudson due to failure to revitalize the drug pipeline, new CEO Belén Garijo is set to take over at the end of April, which may lead to strategic shifts affecting future R&D and market strategies.
See More
Regeneron Launches Gene Therapy and Lowers Drug Prices
- Free Gene Therapy: Regeneron announced that its recently FDA-approved gene therapy, Otarmeni, will be provided free of charge in the U.S. to address an ultra-rare form of genetic hearing loss, enhancing the company's image as a socially responsible biopharma leader.
- Drug Price Adjustments: The company will lower Medicaid prices to match those in other developed nations, notably reducing the price of its blockbuster drug Praluent from approximately $537 to $225, which is expected to significantly alleviate patient financial burdens and enhance market competitiveness.
- R&D Investment Commitment: Regeneron has committed over $9 billion to bolster domestic R&D and manufacturing capabilities over the coming years, a strategic investment that will strengthen its innovation and production capacity in the global biopharma market.
- Policy Context and Market Reaction: As the final biopharma firm to sign Trump's drug pricing agreement, Regeneron's actions align with policy expectations and may improve its investor perception, with bullish sentiment reflected on Stocktwits, despite the stock's 0.8% decline year-to-date.
See More
Trump's Fake Math Claims Spark Controversy
- False Drug Pricing Claims: During a deal announcement with Regeneron, Trump claimed drug prices had been cut by over 100%, a mathematically impossible assertion that reflects a misunderstanding of drug pricing, potentially undermining public trust in his policies.
- Exaggerated Discount Claims: Trump admitted to previously stating that drug prices were reduced by '500% to 600%', attempting to justify this with 'different calculations', yet such claims lack mathematical validity, risking consumer misconceptions about drug pricing.
- Misjudged Iran War Timeline: At the same event, Trump inaccurately claimed the Iran war would conclude within his predicted four to six weeks, while it has actually lasted over seven weeks, which could affect public perception of his foreign policy effectiveness.
- Crowd Size Controversy Resurfaces: Trump revisited the crowd size debate from his 2017 inauguration while discussing renovations at the Lincoln Memorial, claiming it matched Martin Luther King Jr.'s rally, despite lacking supporting evidence, which may further erode his credibility.
See More
Regeneron Lowers Drug Prices and Offers Gene Therapy for Free
- Price Reduction Agreement: Regeneron has agreed to lower drug prices for some Americans as part of a deal with the Trump administration, which may enhance the company's competitive position in the market amid increasing regulatory scrutiny on drug pricing.
- Free Gene Therapy Offering: Following FDA approval, Regeneron will provide its first hearing-loss gene therapy, Otarmeni, for free to eligible U.S. patients, demonstrating the company's commitment to patient care while potentially attracting more users to its innovative products.
- Policy Context: This agreement is part of Trump's 'most favored nation' initiative aimed at tying U.S. drug prices to the lowest prices in other developed countries, and Regeneron's involvement may encourage other pharmaceutical companies to adopt similar pricing strategies.
- Market Potential Assessment: Piper Sandler analysts estimate that the gene therapy could achieve peak sales of $130 million, reflecting the market potential of this treatment for an ultra-rare genetic condition, which could significantly contribute to Regeneron's revenue growth.
See More
Regeneron Agrees to Lower Drug Prices Under Trump Deal
- Price Reduction Agreement: Regeneron has agreed to lower drug prices for some Americans as part of a deal with President Trump, addressing growing concerns over drug affordability and potentially enhancing the company's public image.
- Free Gene Therapy Offering: Following FDA approval, Regeneron will provide its first hearing-loss gene therapy, Otarmeni, for free to eligible U.S. patients, showcasing the company's commitment to social responsibility while attracting more patients to its innovative products.
- Competitive Market Advantage: This agreement is part of Trump's 'most favored nation' policy, which aims to tie U.S. drug prices to the lowest prices in other developed countries, granting Regeneron greater pricing flexibility in a competitive biopharmaceutical market.
- Sales Potential Forecast: Analysts estimate that Otarmeni gene therapy could achieve peak sales of $130 million, reflecting strong market demand and potentially generating significant revenue growth for Regeneron, thereby solidifying its position in the biopharmaceutical sector.
See More
Regeneron's Gene Therapy Otarmeni Receives FDA Accelerated Approval
- FDA Accelerated Approval: Regeneron's gene therapy Otarmeni has received accelerated approval from the FDA, aimed at treating hearing loss caused by gene mutations, marking a significant advancement for the company in the otology treatment space.
- Eligible Patient Population: The therapy is available for adults and children with biallelic variants in the OTOF gene, particularly those with severe-to-profound sensorineural hearing loss who have not undergone cochlear implantation in the same ear, potentially offering new treatment options for this demographic.
- Clinical Trial Support: Data from the company's CHORD trial indicates that 16 out of 20 subjects exceeded a predetermined hearing level 24 weeks after receiving Otarmeni, demonstrating the therapy's efficacy and laying the groundwork for future market introduction.
- Conditions for Continued Approval: The ongoing approval of the drug will depend on positive results from the confirmatory trial, which is currently enrolling patients in countries including the U.S. and the U.K., reflecting Regeneron's commitment to further validating the therapy's effectiveness.
See More
